Galapagos (GLPG) Stock Highlights

24.5 | -1.09%

2025-04-03 04:05:59

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The companys product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohns disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Statistics

Range Today

24.39 25.08

Volume Today 273.2K

Range 1 Year

22.36 32.17

Volume 1 Year 46.49M

Range 3 Year

22.36 72.11

Volume 3 Year 144.04M

Range 10 Year

22.36 274.03

Volume 10 Year 419.98M

Highlights

Market Capitalization 1.68B (small)

Floating Shares 44.55M

Current Price 24.5

Price To Earnings -1.28K

Price To Revenue -5.17

Price To Book 0.58

Earnings Per Share -0.02

Payout Ratio 0%

Performance

Latest -1.09%

1 Month -8.34%

3 Months -12.5%

6 Months -14%

1 Year -23.72%

3 Years -63.02%

5 Years -86.72%

10 Years +0.74%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.